High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases.
Autoimmune disease
Cardiovascular disease (CVD).
Cardiovascular risk
Cholesterol efflux capacity
HDL function
HDL-cholesterol
High-density lipoprotein (HDL)
Journal
Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
30
10
2019
revised:
23
12
2019
accepted:
05
01
2020
pubmed:
11
1
2020
medline:
21
4
2020
entrez:
11
1
2020
Statut:
ppublish
Résumé
Functional assessment of cholesterol efflux capacity (CEC) to high-density lipoprotein (HDL) is an emerging tool for evaluating morbidity and mortality associated with cardiovascular disease (CVD). By promoting macrophage reverse cholesterol transport (RCT), HDL-mediated CEC is believed to play an important role in atherosclerotic lesion progression in the vessel wall. Furthermore, recent evidence indicates that the typical inverse associations between various forms of CEC and CV events may be strongly modulated by environmental systemic factors and traditional CV risk factors, in addition to autoimmune diseases. These factors influence the complex and dynamic composition of HDL particles, which in turn positively or negatively affect HDL-CEC. Herein, we review recent findings connecting HDL-CEC to traditional CV risk factors and cardiometabolic conditions (non-autoimmune diseases) as well as autoimmune diseases, with a specific focus on how these factors may influence the associations between HDL-CEC and CVD risk.
Identifiants
pubmed: 31923386
pii: S0026-0495(20)30005-6
doi: 10.1016/j.metabol.2020.154141
pii:
doi:
Substances chimiques
Cholesterol, HDL
0
Lipoproteins, HDL
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154141Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest AH, EF, SSD and MAF have no conflict of interest to declare. NV received restricted research grants from Roche.